Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer.
Sun Pharmaceutical Industries Ltd. closed 14.48% below its 52-week high of 1,960.20 rupees, which the company reached on ...
The country's top specialty generics company recently acquired US-based Checkpoint that will further its oncology portfolio ...
Welcome to the Sun Pharma Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...
Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...
1d
Brokerages have revealed a favourable outlook for the stock with the acquisition expected to be completed by the second half of 2025.
Hosted on MSN3d
Sun Pharma Share Price Target Raised to Rs 2,400 – Emkay Research Reiterates ‘BUY’ Rating - DetailsLeading brokerage firm Emkay Research has maintained a bullish stance on Sun Pharma, assigning a ‘BUY’ rating with a price ...
Sun Pharma is a top-ranked Indian pharmaceutical firm. The company’s stock has been continuously in the news lately for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback